Sorin Group S.p.A. (SRN) Receives Regulatory Approval to Market Memo 3D(TM) Annuloplasty Ring in Japan  
5/16/2012 10:34:37 AM

TOKYO--(BUSINESS WIRE)--Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announces that it received authorization from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to market its MEMO 3D Semi-Rigid Annuloplasty Ring. The first MEMO 3D implant was performed at the Kobe City Medical Center General Hospital.